TABLE 1 Demographic and clinical characteristics of study subjects
ControlsCF patients
SexAge yearsAtopy#Steroid useSexAge yearsAtopy#Steroid useFEV1 % predP. aeruginosa colonisation+GenotypeUnder AZM treatmentUnder exacerbation§Microorganismsƒ
2F11.3NoNo2M3.8NoNo108NoF508del/F508delNoNoS. aureus
S. pneumoniae
H. influenzae
3M12.1NoNo3F4.7NoNoNDYesF508del/2347delGNoYesS. pneumoniae
Penicillium spp.
4F1.4NoNo4F11YesNo67NoG542X/2708del13YesNoS. aureus
A. fumigatus
5M7.6NoNo5M8.7YesInhaled106NoF508del/F508delNoNoS. aureus
6M12NoNo6M2.6NoInhaledNDYesF508del/F508delNoNoPenicillium spp.
7F14.8NoNo7F9.1YesNo81NoF508del/F508delNoNoS. aureus
8M4.2NoNo8M1.1NoNoNDNoF508del/F508delNoNoS. aureus
H. influenzae
M. catarrhalis
9M1.7NoNo9F15YesSystemic38YesF508del/F508delNoNoS. aureus
11F13.3NoNo11M10.9NoNo62NoNo mutation foundNoNoNone
  • CF: cystic fibrosis; FEV1: forced expiratory volume in 1 s; AZM: azithromycin; F: female; M: male; ND: not determined; S. aureus: Staphylococcus aureus; S. pneumoniae: Streptococcus pneumoniae; H. influenzae: Haemophilus influenzae; A. fumigatus: Aspergillus fumigatus; M. catarrhalis: Moraxella catarrhalis. #: history of hay fever, eczema or asthma; : any treatment with systemic, inhaled or nasal steroids within the previous 3 months; +: at least one Pseudomonas aeruginosa-positive oropharyngeal culture during the previous 12 months; §: defined as by Kieninger et al. [18]; ƒ: present in bronchoalveolar lavage fluid at time of brushing.